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AbsTrACT 
Objective iBD prevalence is estimated to be rising, 
but no detailed, recent UK data are available. the last 
reported prevalence estimate in the UK was 0.40% in 
2003. We aimed to establish the current, and project 
future, prevalence in lothian, Scotland.
Design We conducted an all-age multiparameter search 
strategy using inpatient iBD international classification 
of disease (icD-10) coding (K50/51)(1997–2018), iBD 
pathology coding (1990–2018), primary and secondary 
care prescribing data (2009–2018) and a paediatric 
registry, (1997–2018) to identify ’possible’ iBD cases 
up to 31/08/2018. Diagnoses were manually confirmed 
through electronic health record review as per lennard-
Jones/Porto criteria. autoregressive integrated moving 
average (ariMa) regression was applied to forecast 
prevalence to 01/08/2028.
results in total, 24 601 possible iBD cases were 
identified of which 10 499 were true positives. the 
point prevalence for iBD in lothian on 31/08/2018 
was 784/100 000 (Uc 432/100 000, crohn’s disease 
284/100 000 and iBD unclassified (iBDU) 68/100 000). 
capture–recapture methods identified an additional 
427 ’missed’ cases (95% ci 383 to 477) resulting in 
a ’true’ prevalence of 832/100 000 (95% ci 827 to 
837). Prevalence increased by 4.3% per year between 
2008 and 2018 (95% ci +3.7 to +4.9%, p<0.0001). 
ariMa modelling projected a point prevalence on 
01/08/2028 of 1.02% (95% ci 0.97% to 1.07%) that 
will affect an estimated 1.53% (95% ci 1.37% to 
1.69%) of those >80 years of age.
Conclusions We report a rigorously validated iBD 
cohort with all-age point prevalence on 31/08/2018 of 1 
in 125, one of the highest worldwide.
InTrODuCTIOn
The prevalence of UC, Crohn’s disease (CD) and 
colonic IBD, type unclassified (IBDU), collectively 
termed IBD, in the Western world is reported to be 
increasing.1 Overall IBD prevalence is estimated at 
>0.3% in a recent review, though there is consider-
able geographical variation within this.2 
The current prevalence of IBD in the UK is 
poorly described. Although there have been four 
studies of UK adult IBD prevalence included in a 
recent systematic review, no UK data are available 
for the past 15 years.2 Therefore, the most recent 
estimates of UK IBD prevalence are 9–144/100 000 
for CD and 66–389/100 000 for UC.3 4
While IBD prevalence increases in Westernised 
countries, incidence is seemingly static in these 
populations.2 In contrast to pre-1990 data, where 
75% of CD and 60% of UC studies reported a 
rising incidence, 73% and 83% of post-1990 studies 
show a stable or falling incidence for CD and UC, 
respectively.2 Therefore, while IBD continues to 
be incurable, with significant morbidity but low 
mortality, prevalence will continue to increase. This 
phenomenon of compound prevalence will likely 
affect global IBD epidemiology, as life expectancy 
increases worldwide, but arguably will be greatest 
significance of this study
What is already known on this subject?
 ► IBD incidence appears to be stabilising in 
Western populations though UK data has not 
been reported for >15 years, when prevalence 
was reported at 0.4%.
 ► Recent nationwide data from Canada estimate 
2018 prevalence at 0.7% and introduce the 
phenomenon of compounding prevalence in 
IBD.
What are the new findings?
 ► The point prevalence on 31/08/2018 for IBD in 
Lothian, Scotland, is 1 in 125 (0.8%).
 ► Incidence has been static in the last decade, 
but prevalence rose by 4.3% per year between 
2008 and 2018.
 ► Due to incidence exceeding mortality, 
prevalence will continue to rise (compounding 
prevalence). The projected prevalence in 2028 
for IBD in Lothian is 1 in 98 (1.0%).
 ► In 2028, the number of IBD patients >40 
years of age will exceed the entire current IBD 
population. Moreover, the majority of patients 
with IBD in 2028 will be >50 years old.
How might it impact on clinical practice in the 
foreseeable future?
 ► These data provide current and projected 
prevalence rates that are of immediate utility 
to healthcare providers, resource planning, 
professional bodies and patient groups.
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in developing countries that also have rising incidence.1 This will 
likely have dramatic effects on the number of elderly patients 
with IBD in the future, a cohort that poses significant challenges 
in delay in diagnosis, comorbidity and polypharmacy.5 However, 
understanding the rate of change in elderly IBD prevalence is 
currently poorly described.
Scotland is an attractive nation to perform population-based 
studies. Healthcare is universal and standardised with excellent 
national registries covering >99% of the population for birth, 
mortality and cancer, with individual patient linkage afforded by 
a unique community health index number (https://www. ndc. scot. 
nhs. uk/ Dictionary- A- Z/ Definitions/ index. asp? Search= C& ID= 
128& Title= CHI% 20Number). Capture–recapture is a method 
for estimating the number of individuals in a closed population, 
originally developed by naturalists to estimate species number 
by sampling, marking and releasing animals over numerous 
time points. The same approach can be used in humans to esti-
mate prevalence by comparing multiple, independent datasets 
to ‘capture’ individuals, using statistical modelling to infer the 
number of ‘missed’ cases.6
NHS Lothian Health Board provides all primary and secondary 
care to its residents and serves 16.5% of the Scottish popula-
tion (as of 2018). We aimed to perform an IBD cohort study of 
incidence and prevalence over the past 10 years using capture–
recapture methods to identify those information streams that 
most accurately identified true cases. We then sought to report 
point prevalence on 31/08/2018 and project IBD prevalence in 
2028.
MeTHODs
study population and case identification
Scotland has a population of 5.45 million people (National 
Records for Scotland (NRS) 2016-based 2018 projection, https://
www. nrscotland. gov. uk/ statistics- and- data/ statistics/ statistics- by- 
theme/ population), is located at 56.49oN 4.20oW, with a total 
land area of 77 933 km2. NHS Lothian provides all healthcare 
for a geographically well-defined 897 210 people (NRS 2018 
projection) in Edinburgh and the surrounding area, amounting 
to the second largest residential population in Scotland. Four 
hospitals serve this area (Royal Infirmary of Edinburgh (RIE), 
Western General Hospital (WGH), St John’s Hospital (SJH) and 
the Royal Hospital for Sick Children, Edinburgh (RHSCE)).
We sought to describe the point prevalence of IBD on 
31/08/2018 in Lothian, Scotland. Census data are performed 
every 10 years (most recently in 2011) with NRS reporting 
yearly, mid-year (June) population estimates published retro-
spectively the following April. Mid-2018 population projections 
were used for 31/08/2018 point prevalence reporting, based on 
2016 estimates, as these were the most current data at time of 
submission.
‘Possible’ IBD cases were identified using the six informa-
tion sources detailed in figure 1 and subjected to manual case 
verification using protocolised review of the electronic health 
record (EHR) and Lennard-Jones/Porto criteria by a team of 
eight IBD physicians. The EHR contains all secondary care inter-
actions since 2009 using the TrakCare (InterSystems Corpora-
tion, Cambridge, Massachusetts, USA) system across all Lothian 
sites. Where diagnosis was not clear, an expert panel of three 
IBD physicians reviewed the cases. All six information streams 
capture the entire Lothian population, but over different time 
periods, as discussed below.
Histopathology processing and analysis for IBD was histori-
cally performed at two sites (RIE and WGH) for the whole of 
NHS Lothian, and a single site (WGH) for the last 10 years. Tissue 
samples have been coded prospectively for diagnoses since 1988 
but recorded electronically since 1990. The pathology database 
was interrogated for IBD cases from 01/01/1990 to 31/8/2018 
by a consultant IBD histopathologist.
All hospital admissions in NHS Lothian have been coded 
within TrakCare since 01/08/2006 using international classifi-
cation of disease (ICD-10) criteria. K50 (Crohn’s disease), K51 
(UC) and K52 (Other unspecified non-infective gastroenteritis 
and colitis) codes were obtained where they appeared anywhere 
within the discharge summary. We included all K52 codes 
(K52.3 is IBDU) to ensure IBD/IBDU cases that were incorrectly 
coded or where the diagnosis was ultimately changed, were also 
captured. Information Services Division Scotland also collects 
data on K50/51 admission codes as part of routine data capture 
for the Scottish government that predates the EHR system to 
01/01/1997. In-patient K50/51 coding data were therefore 
obtained from 01/01/1997 to 31/03/2018, with K52 coding 
available in addition from 01/08/2006.
Primary care prescribing in Lothian is standardised using 
a joint formulary and complete for all prescribed drugs from 
01/04/2009. Due to requisite monitoring of immunomodulator 
drugs, all IBD patients prescribed these medications are seen 
in secondary care and therefore identified from the specialist 
clinic attendance (see below). We hypothesised that IBD patients 
with a benign natural history may not have been captured from 
other information streams (e.g. no hospital admission, pre-1990 
or no recorded pathology). We therefore assessed mesalazine 
prescribing (British National formulary section 5.1) in primary 
care from 01/04/2009 to 31/03/2018.
Prescribing of biological agents in IBD (infliximab, adali-
mumab, ustekinumab, vedolizumab) in Lothian is exclusively 
performed in secondary care and requires regular monitoring 
including yearly secondary care review and bi-annual virtual 
biologic clinic review. A prospective adult Lothian biological 
Figure 1 Information sources used for IBD case identification. The 
number of unique cases of putative IBD identified from each 
information stream, and overall, during the described capture period. 
All gastroenterology secondary care outpatient appointments between 
01/08/2017 and 01/08/2018 at the largest Lothian IBD centre (Western 
General Hospital) were screened in addition to estimate accuracy of 
our search strategy. All ‘possible’ cases were then submitted to manual 
review of the electronic medical record. 
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database in IBD has been held since 01/08/2009; all entries were 
therefore submitted for case verification.
Outpatient clinic attendances in secondary care are recorded 
electronically on the EHR, but not universally coded using 
ICD-10 (RIE but not SJH, WGH or RHSC), in contrast to the 
inpatient admission data. We therefore screened all GI clinic 
attendances from the largest hospital that does not code outpa-
tient attendances (WGH) that also provides the vast majority of 
specialist IBD care, from 01/08/2017 to 31/08/2018, to assess 
the completeness of our search strategy.
The specialist paediatric IBD service at RHSCE acts as a dedi-
cated central referral centre for all district general hospitals within 
a strict geographical area of South-East Scotland (based on post-
code). Since 1997, all incident and prevalent cases of paediatric 
IBD managed within South-East Scotland have been prospec-
tively recorded on a custom-made database which is regularly 
updated to capture patient immigration, emigration, transition 
to adult services and death, to ensure accurate prevalence figures. 
All cases are validated according to the revised Porto criteria and 
no age limitation is placed to ensure full capture of all patients 
being cared for in paediatric services. All prevalent IBD cases at 
31/08/2018 confined to Lothian postcodes and cared for within 
paediatric services were added to the above identified adult cases.
Incident adult IBD cases between 2008 and 2017 were 
obtained by documenting the date of diagnosis during the 
EHR verification process by manual case review of pathology, 
endoscopy reports where necessary and EHR (that includes all 
secondary care attendance). Incident cases were reported per 
calendar year and per 100 000 population calculated using the 
mid-year population estimates (NRS) for that calendar year.
Data linkage
All confirmed IBD cases were cross-matched against the national 
mortality registry, and the EHR for last known postcode (all 
secondary care patient interactions require address details to be 
confirmed as being current) to identify prevalent cases. WGH 
and RIE take tertiary care referrals from other non-Lothian 
hospitals, therefore, only postcodes exclusive to NHS Lothian 
Health Board were used to identify prevalent cases.
statistical analysis
JMP V.14 (SAS Software, Copyright © (2019) SAS Institute 
Inc, Cary, North Carolina, USA) and Prism V.7.00 (GraphPad 
Software, La Jolla, California USA, www. graphpad. com) were 
used for statistical analyses and generation of graphs. Descrip-
tive statistics are presented as medians with IQR for continuous 
variables and frequencies with percentages for categorical vari-
ables. For comparison of nonparametric continuous variables, 
the Mann-Whitney U test or Kruskall-Wallis test was used where 
appropriate. For comparison of categorical variables, the χ2 test 
was used. A p value of <0.05 was considered significant for all 
statistical tests. Trends in incidence, prevalence and mortality 
over time were reported as annual percentage change, calculated 
by exponentiating the beta-coefficient of Poisson regression 
and subtracting 1. Poisson modelling was also used to calculate 
significance in these trends over time.
In epidemiology, capture–recapture approaches estimate the 
degree of incomplete case ascertainment using overlapping 
case lists from multiple sources. A three-source model using 
the best performing information sources (termed A, B and C) 
was employed as this has been shown to be optimal in other 
diseases.6 Loglinear Poisson regression was used to explore the 
dependence between sources using interaction terms. We thus 
generated a dataset with four variables (A, B, C and frequency) 
where A, B and C were equal to 0 or 1 (0=not identified in 
this source, 1=identified in this source) and frequency deter-
mined the number of cases identified from each combination of 
A, B and C. The goodness of fit for each model combination 
was assessed using deviance and the derived Bayesian infor-
mation criterion (BIC) with the lowest BIC model selected. To 
derive missing case number, the model was used to estimate case 
frequency when A+B+C=0.
To estimate future prevalence, we used an autoregressive (AR) 
integrated (I) moving average (MA)(ARIMA) model. This anal-
ysis relies on historical values at regular time intervals with the 
assumption of stationarity to model future values. The ARIMA 
model is a time series analysis used extensively in economic and 
prevalence forecasting as it permits analysis at a specific time 
point relative to previous dependent, equally spaced, discrete 
data and has been used to forecast IBD prevalence in recent 
nationwide analysis.1 We therefore used standard Box-Jenkins 
ARIMA methodology to assess the ability of AR or MA model-
ling after differencing, if required, to forecast future prevalence. 
Observed prevalence (using prevalent cases from 01/01/2008 to 
01/08/2018 at monthly intervals, standardised for the mid-pop-
ulation estimates from that calendar year from NRS data and not 
including estimated missed cases from capture–recapture meth-
odology) for all IBD and for individual age groups (<17, 17–39, 
40–59, 60–79 and >80 years) were imputed to JMP V.14.
First, stationarity of the dataset was assessed. Where station-
arity was not observed, differencing was used to achieve station-
arity. All the prevalent age groupings and IBD prevalence overall 
required one mode of differencing to achieve stationarity. There-
after, AR or MA models were compared for best fit using Akaike 
Information Criterion (AIC), BIC and Root Mean Square Error 
(RMSE) for each AR/MA combination. The model with the 
lowest AIC/BIC and RMSE was used. A differencing of 1 and AR 
Figure 2 The point prevalence of IBD in Lothian on 31/08/2018. True 
and false positive cases were identified from ‘possible’ cases in figure 1 
and used to define accuracy rates for each information stream (Table 3). 
True positives were screened for prevalent (Lothian postcode) and 
live (linkage to national datasets) cases to report point prevalence on 
31/08/2018. 
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model without intercept produced the best fit for total cohort 
prevalence. A simulated time lapse using the ARIMA model was 
then undertaken to 01/08/2028 and reported with 95% predic-
tion intervals. The forecast number of prevalent IBD cases per 
age group in 2028 were then derived from NRS mid-year popu-
lation estimates.
ethical considerations
Data are reported according to the Strengthening the Reporting 
of Observational Studies in Epidemiology statements.7
resulTs
IbD point prevalence on 31 August 2018
There were 7035 prevalent IBD cases in Lothian (2552 CD, 3877 
UC and 606 IBDU) (figure 2) conferring a point prevalence on 
31/08/2018 of 784/100 000 (284/100 000 for CD, 432/100 000 
for UC and 68/100 000 for IBDU) (figure 2 and table 1).
The IBD point prevalence on 31/08/2018 was 776/100 000 
(women) and 796/100 000 (men) with prevalence highest in 
women aged 50–59 and men aged 70–79 (1.24% and 1.38%, 
respectively, figure 3). There was no association between post-
code and IBD prevalence nor incidence (online supplementary 
figure 1). When stratified by age group, the measured point 
prevalence on 31/08/2018 was 106/100 000 for <17 years 
old, 652/100 000 for 17–39 years old, 1124/100 000 for 
40–59 years old, 1178/100 000 for 60–79 years old and 
1042/100 000 for >80 years old groups (online supplementary 
table 1).
The annual average percentage change in prevalence rose 
significantly between 2008 and 2018 at 4.3% (95% CI 3.7 
to 4.9) per year (p<0.0001)(Table 2). The proportion of 
IBD subtypes within the prevalent cohort over this time was 
unchanged, suggesting the prevalence of IBD subtypes was 
increasing uniformly (online supplementary figure 2).
Information source accuracy
In total, 24 601 unique possible IBD cases were identified 
from pathology coding (n=7742), hospital admission coding 
(K50/51/52 coding (2006–2018) n=15 879, K50/51 coding 
(1997–2018) n=6711), primary care prescribing of mesalazine 
(n=6035), IBD biological prescribing (n=842) and paediatric 
cases (n=122) (Table 3 and online supplementary figure 3).
Possible IBD cases were screened manually by EHR review, 
leaving 10 499 true positives (Table 3). Inpatient coding 
(restricted to K50/51) correctly identified IBD in 75% of cases, 
with 53% of the cohort hospitalised for any indication since 
1997 (Table 3). To identify prevalent cases, postcode and death 
linkage analysis was performed, with 2244 patients possessing 
a non-Lothian postcode and 1220 patients deceased as of 
31/08/2018, which were thus excluded (figure 2).
The optimum search strategy using the minimum number of 
data streams was pathology plus K50/51 coding and mesalazine 
prescribing, which identified 94.6% of true positives (online 
supplementary figure 3). Without manual EHR review, this 
strategy would overestimate the number of IBD cases by 6.0%, 
which increased to 17.0% if pathology was removed from the 
algorithm (online supplementary figure 4 and Table 3).
Table 2undefined Standardised prevalence per 100 000 population 
for Lothian on 31 August between 2008 and 2018
Year Population
Prevalent IbD cases per 100 000 population
uC CD IbDu All
2008 808 940 315 216 36 567
2009 816 510 334 224 38 596
2010 825 520 349 232 41 621
2011 836 610 359 242 43 644
2012 843 740 375 249 47 671
2013 849 720 386 258 51 694
2014 858 120 398 265 56 719
2015 867 800 411 270 59 739
2016 880 000 418 274 62 753
2017 889 450 427 278 66 772
2018 897 210 432 284 68 784
CD, Crohn's disease; IBDU, IBD unclassified.
Table 1 Overview of the demographic information for prevalent IBD 
cases in  the Lothian IBD registry on 31/08/2018
Variable
CD
(n=2552)
uC
(n=3877)
IbDu
(n=606)
Female (n (%)) 1403 (55.0) 1868 (48.2) 305 (49.0)
Age (Median, IQR) 49.1 (34.8–62.4) 52.6 (39.4–65.9) 51.0 (37.6–63.0)
Age at diagnosis (Median, 
IQR) 29.4 (21.0–45.6) 36.8 (26.1–50.1) 42.0 (27.6–54.5)
Disease duration (Median, 
IQR) 11.7 (5.7–20.7) 10.7 (5.4–18.7) 6.9 (3.5–12.2)
CD, Crohn's disease; IBDU, IBD unclassified.
Figure 3 Age group prevalence breakdown by sex and IBD classification. Prevalent IBD cases were subdivided into age groups by IBD diagnosis 
into all IBD (red) and UC, CD or IBDU (blue). Percentage prevalence is reported for age-appropriate population data derived from National records for 
Scotland, 2016-based projections for 2018. CD, Crohn's disease; IBDU, IBD unclassified.
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To identify the number of missed cases from our identification 
process, loglinear Poisson regression was applied to the three 
best performing information streams (K50/51 coding (A), mesal-
azine prescription (B) and pathology (C)). Loglinear models 
were compared for BIC, deviance and R2 using multiple interac-
tion terms between information streams to identify the optimum 
model (A, B, C with AB and AC interaction terms, R2=0.98, 
deviance=17, BIC=93, p<0.001). We therefore estimate that 
427 cases (95% CI 383 to 477) have escaped our information 
capture. When combining observed and missed cases, we esti-
mate the ‘true’ prevalence of IBD to be 832/100 000 (95% CI 
827 to 837) and report the completeness of our registry to be 
94.3% (95% CI 93.7 to 94.8).
Incidence, mortality and age at diagnosis
IBD incidence was 40.8/100 000 patient years in 2017 
(19.8/100 000 UC, 13.6/100 000 CD and 5.4/100 000 IBDU) 
(figure 4A and B and table 4). However, in contrast to prev-
alence, IBD incidence per calendar year from 2008 to 2017 
was static, with no significant change overall (annual average 
percentage change 14.4%; 95% CI −0.9 to +32.1, p=0.66).
Mortality of the prevalent population per calendar year did 
not change significantly between 2008 and 2017 (annual average 
percentage change in mortality 10.5%, 95% CI −18.8 to +50.0, 
p=0.52)(figure 4A). Age at diagnosis peaked in the 18–29 age 
group in all IBD subtypes and overall, falling thereafter with 
increasing age in UC and CD, but with an even age distribution 
in IBDU (figure 4C and D).
Projected IbD prevalence in 2028
The forecast point prevalence for IBD in Lothian on 01/08/2028 
is 1023/100 000 (95% CI 975 to 1071), which equates to 9681 
people (95% CI 9393 to 10 329) (figure 5A).
When stratified by age group, the estimated point prevalence 
on 01/08/2028 is 124/100 000 for <17 years old (95% CI 80 
to 169), 804/100 000 for 17–39 years old (95% CI 718 to 890), 
1479/100 000 for 40–59 years old (95% CI 1416 to 1542), 
1537/100 000 for 60–79 years old (95% CI 1464 to 1610) and 
1530/100 000 for >80 years old (95% CI 1368 to 1692) groups, 
respectively (figure 5A).
This equates to 210 aged under 17 (95% CI 135 to 284), 2478 
aged 17–39 (95% CI 2213 to 2743), 3635 aged 40–59 (95% CI 
3479 to 3790), 2928 aged 60–79 (95% CI 2788 to 3067) and 
776 aged >80 (95% CI 694 to 858) patients with IBD in Lothian 
on 01/08/2028 (figure 5B).
We conducted a secondary analysis of prevalence projec-
tions in 2028 using total count of prevalent cases (vs propor-
tion of background population in primary analysis). Using 
total prevalent count resulted in a similar prevalence estimate, 
with a forecast 01/08/2028 prevalence of 993/100 000 (95% 
CI 956 to 1031) for all IBD. Lastly, by simply applying the 
annual percentage change from Poisson regression between 
2008 and 2018 to 2028, a similar estimated IBD prevalence 
was reported as in the primary analysis (1252 95% CI 1151 to 
1362/100 000).
Table 3undefined Accuracy of IBD case identification information 
streams
Data source
True positives 
n / %
False positives 
n / %
% of total 
true positives 
identified
Pathology coding 7661 (99) 81 (1) 73
ICD-10 code K50/51 5525 (75) 1186 (25) 53
Mesalazine prescribing 5079 (84) 956 (16) 48
ICD-10 code K50/51/52 4254 (27) 11 625 (73) 40
Secondary care prescribing 842 (100) 0 8
Paediatric registry 122 (100) 0 1
Total unique cases 10 499 14 102
All true positive, live Lothian or non-Lothian resident IBD cases identified from 
manual case review of ‘possible’ cases were used to derive the accuracy of each 
information stream. The proportion of cases accepted as true positive (ie, IBD) or 
false positive (ie, non-IBD) for each information stream is presented, in addition to 
the proportion of all true positives.
Figure 4 Incidence, mortality and age at diagnosis by IBD subtype changes between 2008 and 2018. Incident cases were identified by using the 
date of diagnosis obtained during case verification. Mortality data were obtained from national registry linkage. Incidence and prevalent IBD cohort 
mortality (A), with IBD subtype incidence breakdown (B), age at diagnosis for prevalent cases on 31/08/2018 overall (C) and for IBD subtype (D). CD, 
Crohn's disease; IBDU, IBD unclassified. 
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DIsCussIOn
We describe a comprehensive prevalence analysis of IBD in a 
defined geographical area of Scotland supporting approximately 
900 000 people. Data capture–recapture techniques show that 
pathology coding was the most accurate information stream in 
identifying true positives in the prevalent population and overall. 
However, a lack of significant dependence between informa-
tion streams supports an approach to prevalence measurement 
that uses multiple information sources. This has important 
ramifications for previous studies that have relied on in-patient 
coding alone, as this underestimated prevalence in our cohort by 
47%. We show that it is possible in our cohort to identify 95% 
of true positives with only 6% false positives using the combina-
tion of primary care prescribing of mesalazine, inpatient ICD-10 
K50/51 coding and histopathology sources.
A recent nationwide historic, and future-predicted, prevalence 
IBD analysis has been published in the Canadian population. 
They report an estimated prevalence of 0.7% in 2018, forecast 
to rise to 1% of Canadians by 2030.2 We report a similar point 
prevalence of 0.78% on 31/08/2018 but this may be as high as 
0.83% when missed cases from capture–recapture analysis are 
included. This surpasses the most recent UK prevalence esti-
mates in 2003 of 0.4% (equivalent to 221 000 of the 2003 UK 
population) and that of >0.3% (range 0.27% (Southern Europe) 
to 0.77% (Northern Europe)) from recent systematic review of 
North America and Europe prevalence.2 4 We report some of 
the highest incidence of UC, CD and IBDU in the literature. 
IBDU incidence in particular was high at 5.4/100 000 in 2018. 
However, IBDU incident and prevalent cases as a proportion of 
all IBD was unchanged over the 10-year study period, suggesting 
IBDU is not increasing in our cohort.
Compound prevalence is the phenomenon whereby incidence 
exceeds mortality, such that prevalence inexorably increases. 
Western populations with chronic conditions of stable incidence 
and low mortality are most sensitive to this, which accompanied 
with the ageing population has important considerations for 
healthcare provision. In IBD, this has several important nuances. 
For example, the need for increased use of immunomodulator 
drugs in the elderly, whom may have more frequent hospitalisa-
tions, greater postoperative mortality and in particular thrombo-
embolic risk compared with younger patients.5 8
While the overall direct healthcare costs for IBD are forecast 
to rise (€161 to €661 million between 2011 and 2040 in the 
Netherlands), current estimates suggest IBD patients ≥60 years 
may account for only 1% of this.9 This may reflect a low level of 
anti-TNF use (25.3% vs 13.1%, p<0.001 in <60 years vs ≥60 
years, respectively), with anti-integrin use not reported.9 It is 
likely that increased use of JAK inhibitors, anti-integrins and 
access to biosimilar anti-TNF will only increase the >60 years 
share of total IBD cost, thus future studies to assess health-eco-
nomic effects of compound prevalence in IBD are needed.
The suggested use of immunomodulators to reduce faecal 
biomarkers irrespective of symptoms10 will have important 
Table 4undefined Incident cases and standardised incidence per 100 000 per calendar year for Lothian between 2008 and 2017
Year
background 
population
(mid-year estimates)*
uC CD IbDu All
number of 
cases
Per 100 000 
per year
number of 
cases
Per 100 000 
per year
number of 
cases
Per 100 000 per 
year
number of 
cases
Per 100 000 per 
year
2008 808 940 168 20.77 88 10.88 37 4.57 293 36.22
2009 816 510 191 23.39 104 12.86 30 3.71 325 40.18
2010 825 520 178 21.56 121 14.96 31 3.83 330 40.79
2011 836 610 164 19.60 141 17.43 32 3.96 337 41.66
2012 843 740 197 23.35 110 13.60 40 4.94 347 42.90
2013 849 720 167 19.65 131 16.19 46 5.69 344 42.52
2014 858 120 180 20.98 121 14.96 48 5.93 349 43.14
2015 867 800 203 23.39 104 12.86 39 4.82 346 42.77
2016 880 000 164 18.64 107 13.23 42 5.19 313 38.69
2017 889 450 176 19.79 110 13.60 44 5.44 330 40.79
*Census data are presented for 2011, the remaining population estimates are taken from NRS mid-year (June) population estimates.
CD, Crohn's disease; IBDU, IBD unclassified; NRS, National Records for Scotland. 
Figure 5 Projected IBD prevalent cases±95% CI from 2018 to 2028. 
Retrospective prevalence data were imputed monthly from 01/01/2008 
to 31/08/2018 to model age-group projected future prevalence to 
31/08/2028 (A), with absolute prevalent case number per age group 
for actual prevalence on 31/08/2018 and projected prevalence on 
01/08/2028 (B). 2016-based population projections were obtained from 
2018 to 2028 from National records for Scotland data.
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ramifications for an IBD population of the future whom are 
mostly >50 years old. For example, recent ECCO practice posi-
tion urges careful consideration for thiopurine use in the elderly11 
(HR for lymphoma 5.3, absolute risk 1 in 300 for >70s), yet 
anti-TNF monotherapy is associated with immunogenicity.
In addition, the median age of patients in ACCENT-1, SONIC 
and CHARM trials were all <40 years (IQR <15 years), with 
no patients enrolled >80 years of age (eldest patient in SONIC 
combination therapy arm was 68 years).12–14 The efficacy of 
IBD treatments in controlled trials of the future should include 
a distribution of ages representative of our population, not least 
due to increasing polypharmacy (and therefore drug–drug inter-
actions) and immunosenescence within the elderly.15 16
The strengths of the current analysis include the manual verifica-
tion of all cases using multiple information sources, capture–recap-
ture methodology and the reporting of actual prevalence for the 
past 10 years to guide future estimates. For example, manual review 
of EHR (including date of diagnosis calculation) ensures that the 
likelihood for incident cases diagnosed pre-2008 being carried over 
is highly unlikely. The main weakness is that despite our rigorous 
efforts to identify IBD patients, cases may have escaped capture 
from our data sources leading to an underestimation of IBD preva-
lence. Capture–recapture methods assume a closed population that 
each capturing stream is independent and that all members have 
the same probability of being captured. These assumptions are diffi-
cult to satisfy completely in epidemiological studies, thus despite 
our estimation of missed cases, results herein are best interpreted as 
minimum prevalence rates in all cases.
For example, those patients with an IBD diagnosis made pre-1990 
and who had no further contact with any secondary care and no 
history of immunomodulator nor mesalazine usage would be 
missed. However, we believe this number will be very small. Simi-
larly, while efforts were made to identify whether patients had left 
our health board during case review, it is likely that some patients 
have left the area without our knowledge. However, we believe that 
this will be augmented by the overall net migration within Lothian 
(0.9% of total 1.07% population change between 2016 and 2017 
was migration) of which 73% were <34 years of age.
The increased projected healthcare burden of IBD in the next 10 
years is set against significant predicted challenges to the NHS over 
the same period. The UK had among the lowest number of gastroen-
terologists per head of population in 2007 (1.4 vs 3.5 in France and 
3.9 in the USA per 100 000).17 This has increased to 2.3/100 000 
(https://www. bsg. org. uk/ resource/ workforce- report- 2018. html), yet 
resources remain scarce to manage IBD patients presently, or the 
increases we project over the coming 10 years. Innovative strate-
gies for IBD care delivery are therefore required. These are likely 
to include more capacity for acute IBD flare review, distance moni-
toring of disease through home calprotectin and diversification of 
the physician–patient interaction through e-health and videoconfer-
encing solutions.
In summary, we report detailed multiparameter information 
capture–recapture techniques to describe the prevalence of IBD 
in Lothian, Scotland. We show 1 in 125 currently have IBD, 
and this is forecast to rise to 1 in 98 within 10 years. The IBD 
physician of the future will need to be attuned to the ageing 
demographic of their patients, with important implications for 
treatment decisions and healthcare provision.
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